AbbVie Inc.
Close on Oct 19, 2026
- Market cap
- $500.63B
- P/E (TTM)
- 79.9
- Dividend yield
- 2.35%
Earnings
Next report expected Oct 30, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 31, 2026 | Before market open | $16.99B | $2.03 | $3.65 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 29, 2026 | Before market open | $15.00B | $0.39 | $2.65 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 4, 2026 | Before market open | $16.62B | $1.02 | $2.71 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 31, 2025 | Before market open | $15.78B | $0.10 | $1.86 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | Before market open | $15.42B | $0.52 | $2.97 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 25, 2025 | Before market open | $13.34B | $0.72 | $2.46 |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 31, 2025 | Before market open | $15.10B | $-0.02 | $2.16 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | Before market open | $14.46B | $0.88 | $3.00 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 25, 2024 | Before market open | $14.46B | $0.77 | $2.65 |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 26, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 2, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 31, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| adjusted diluted EPSnon-GAAP | full year 2026 | $13.87 to $14.07 | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements AbbVie filed with the SEC
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Completes Acquisition of Apogee Therapeutics
Regulation FD disclosure · EX-99.1 to Form 8-K
AbbVie Reports Second-Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
Regulation FD disclosure · EX-99.1 to Form 8-K
AbbVie Reports First-Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Reports Third-Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Reports Second-Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Reports First-Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Reports Third-Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Reports Second-Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Reports First-Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Announces Appointment of Robert
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AbbVie Completes Acquisition of ImmunoGen
Regulation FD disclosure · EX-99.1 to Form 8-K
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction
Regulation FD disclosure · EX-99.1 to Form 8-K
to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite
Regulation FD disclosure · EX-99.2 to Form 8-K
AbbVie to Acquire ImmunoGen, including
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
AbbVie Reports Third-Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Reports Second-Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Reports First-Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
Results of operations · EX-99.1 to Form 8-K
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K